Healthcare Sales & Marketing Network News: Farletuzumab

Searching News Database: Farletuzumab

HSMN NewsFeed - 10 Jan 2018
Morphotek Announces FDA Acceptance Of Investigational New Drug Application For Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Sep 2017
Morphotek(R), Inc. Announces an Agreement with Fujirebio Diagnostics, Inc. to Commercialize the CA125 II Assay as a Companion Diagnostic for Farletuzumab(R)
Biopharmaceuticals Diagnostics Oncology Licensing

HSMN NewsFeed - 1 Jul 2009
Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Mar 2009
Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Apr 2008
European Regulatory Agency Grants Orphan Status to Morphotek(R)'s Farletuzumab and MORAb-009
Biopharmaceuticals Oncology Regulatory

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.